← FDA DRUG APPROVALS

FDA NDA · NDA021019

COMPAZINE

Sponsor: GLAXOSMITHKLINE

APPLICATION
NDA021019
TYPE
NDA
ORIGINAL APPROVAL
1999-10-06
LATEST ACTION
2001-04-03
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

COMPAZINEDiscontinued
PROCHLORPERAZINE MALEATE EQ 15MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
COMPAZINEDiscontinued
PROCHLORPERAZINE MALEATE EQ 10MG BASE · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2001-04-03Labeling · Supplement 1 · standard — Letter ↗AP
1999-10-06Type 3 - New Dosage Form · Original · standard — Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →